Bryan Burt
Division Chief · UCLA David Geffen School of Medicine/UCLA Medical Center
Credentials: · · · · · · · ·
History
- Present
Thoracic Surgery Division · UCLA David Geffen School of Medicine/UCLA Medical Center
- Present
Department of Surgery Division · UCLA David Geffen School of Medicine/UCLA Medical Center
- 2011–2012
- 2006–2012
- 2003–2006
Research
Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity
Nature · 2015 · 190 citations
Human liver dendritic cells promote T cell hyporesponsiveness
The Journal of Immunology · 2009 · 179 citations
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors
Cancer Cell · 2024 · 174 citations
- SG
27 papers
26 papers
- DS
25 papers
- MH
17 papers · 2 as a resident
12 papers
- FK
10 papers
10 papers
- NP
9 papers
Grants
- 2026–2031
Digital Biomarkers and Remote Testing for Neurogenic Thoracic Outlet Syndrome
National Institute of Child Health and Human Development · R01
Contact PI · $484.1K · University of California Los Angeles
- 2023–2028
National Cancer Institute · R01
PI · $2.4M · Baylor College of Medicine
- 2021–2027
Proteomic Determinants of Response to Checkpoint Blockade in Malignant Pleural Mesothelioma
National Cancer Institute · R37
Contact PI · $2.9M · University of California Los Angeles
- 2016–2018
Allogeneic Antibody Therapy for Malignant Mesothelioma
National Cancer Institute · R03
Contact PI · $158.5K · Baylor College of Medicine
Clinical trials
- 2020–2021
Cyclosporine For The Treatment Of COVID-19(+)
Principal investigator · Completed · Phase 2
Bryan Burt, MD
- 2019–2023
MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma
Principal investigator · Unknown · Phase 2
Momotaro-Gene Inc.
- 2016–2022
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Principal investigator · Completed · Phase 2
Baylor College of Medicine